Regarding “Ultrasound findings after radiofrequency ablation of the great saphenous vein”  by Goldman, Mitchel P. & Weiss, Robert A.
ment of her arteritis with antitumor necrosis factor-. Antitumor
necrosis factor- inhibits granuloma formation, and there are
many reports of tuberculosis after its use.5-6
As is the case with most vasculitides, the etiology of Takayasu
arteritis is not known. There is considerable overlap with other
syndromes of large-vessel arteritis. Not all evidence points toward
tuberculosis as a cause, and other pathophysiologic mechanisms
have been proposed. Nevertheless, the association between Taka-
yasu arteritis and Mycobacterium tuberculosis is an intriguing one
and awaits further study.
Ian R. McPhail, MD
Cardiovascular Diseases and Interventional Radiology
Mayo Clinic
Rochester, Minn
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Reply
I thank Dr McPhail for his insightful and interesting com-
ments. I would certainly agree with him that we did not address the
etiology of Takayasu’s arteritis. The focus of the case report was to
describe a rare form of graft infection by Mycobacterium tubercu-
losis and its successful treatment as well as briefly summarize the
bacterial etiology and treatment of aortic graft infections in gen-
eral. It was not our intention to discuss the association of Takaya-
su’s arteritis with M. tuberculosis.
Dr McPhail has raised some very interesting issues about the
etiology of Takayasu’s arteritis and the possible connection with
tuberculosis. Of course there is a challenge in trying to attribute
causation (as with Crohn’s disease or sarcoidosis) as opposed to
association. The association between Takayasu’s arteritis and tu-
berculosis has been noted and is well referenced by Dr. McPhail.
But one third of the world’s population is infected with tubercu-
losis (World Health Organization), and that number is much
higher in India and similar places. Again, the association does not
ascribe causality: the same immune defect that causes the arteritis
may permit activation of latent tuberculosis infection.
To the best of our knowledge M. tuberculosis antigens have
not been found in the arterial wall of patients with Takayasu’s
arteritis or other vasculitides. We certainly agree with Dr McPhail
and the references provided that in the case we have described, the
patient’s quiescent tuberculosis was reactivated by infliximab
(Remicade, Centiocor, Inc, Malvern, Pa), an anti-tumor necrosis
factor- monoclonal antibody.
Joseph D. Raffetto, MD
VA Boston Healthcare System
West Roxbury, Mass
doi:10.1016/j.jvs.2005.02.016
Regarding “Ultrasound findings after radiofrequency
ablation of the great saphenous vein”
Wewould like to comment on the article by Salles-Cunha et al:
Ultrasound findings after radiofrequency ablation of the great
saphenous vein: Descriptive analysis (J Vasc Surg 2004;40:1166-
1173). The development of the radiofrequency (RF) closure tech-
nique for treating the incompetent great saphenous vein (GSV)
was completed by multiple specialties, with dermatology taking a
significant role.1,2 Dermatologic surgeons were the first to apply
tumescence to ambulatory phlebectomy and/or ligation of the
GSV and its tributaries.3,4 We therefore used tumescent anesthesia
with radiofrequency or other energies for endoluminal closure/
ablation of the GSV. Tumescent anesthesia or the placement of
large volumes of dilute anesthesia in a perivascular position serves
several purposes: first, to protect perivascular tissues from the
thermal effects of intravascular energy such as RF; second, to
decrease the diameter of the treated vein to allow for better contact
of the RF electrodes with the vein wall, and thus secondarily to
reduce intravascular blood for nonspecific coagulation; and third,
to provide better and safer anesthesia for patients. All of these
effects should serve to reduce perivascular inflammation.
Our initial results showed that tumescent anesthesia to treat
the GSV with endovenous techniques resulted in a painless proce-
dure with little down-time and immediate ambulation of the
patient.1,2,5,6 Regarding RF closure, we now have up to 5 years of
follow-up on 125 (M.P.G.) and 627 (R.A.W.) patients. We also
have treated patients with intravascular lasers, including the
810-nm diode laser, with up to 3 years of follow-up (75 patients,
M.P.G.; 36 patients, R.A.W.), and an additional 143 patients with
the 1,320-nm intravascular neodymium:yttrium-aluminum-garnet
laser with up to 2 years of follow-up (43 patients, M.P.G.; 121
patients, R.A.W.).7 Our combined clinical experience with en-
dovenous techniques spans 5.5 years, with well over 1,000 patient
treatments. Posttreatment duplex evaluation data at regular time
intervals exists on the vast majority of these patients.
Contrary to what is reported by Salles-Cunha et al, our expe-
rience with tumescent anesthesia used in every one of our patients
is a complete lack of small-vessel networks when patients are
evaluated postoperatively with duplex ultrasound. We believe that
the reason for our failure to find small-vessel networks is not a lack
of trying to see them but rather the minimization of inflammation
that occurs with tumescent anesthesia placed in the perivascular
space during either RF or laser endothelial ablation.
We have not performed ligation of the saphenofemoral junc-
tion (SFJ) on any of our over 1,000 patients and question the
accuracy of the findings of Salles-Cunha et al, who found a de-
creased incidence of small-vessel networks in patients whose SFJs
were ligated. We suspect that the small number of patients who
were treated without ligation of the SFJ (13) vs the 93 patients
who did have SFJ ligation produced the false statistical significance
of this finding. Alternatively, if inflammation is the most likely
cause for small vessel networks, why would ligation decrease the
extent or time of inflammation?
Finally, the investigators admit to performing ligation of all
tributary veins at the time of ligation at the SFJ. Could it be
possible that ligating and disrupting the normal vascular system at
the SFJ results in a decrease in the normal number of small-vessel
networks and that this accounts for the decrease seen in patients
operated on vs patients in whom only the RF is performed?
We are curious about why none of the five studies that we
published were not cited in the Salles-Cunha et al publica-
tion.1,2,5-7 We support efforts to share information across special-
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ties because this ultimately improves the quality of patient care.
And that, or course, is the goal that all medical and surgical
specialties and subspecialties ultimately share.
Mitchel P. Goldman, MD
Robert A. Weiss, MD
University of California, San Diego
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Regarding “Ultrasound findings after radiofrequency
ablation of the great saphenous vein:
Descriptive analysis”
The letter by renowned dermatologic specialists, Mitchel P.
Goldman, MD, and Robert A. Weiss, MD, touches on the follow-
ing topics of importance: (1) tumescent anesthesia; (2) experience
with endovascular treatment of the saphenous vein, including
radiofrequency ablation (RFA); (3) regular post-treatment fol-
low-up with duplex ultrasound evaluation; (4) complete lack of
small vessel network; (5) why ligation may decrease inflammation
and, by association, small vessel networks; and (6) concerns ex-
pressed regarding lack of reference to their work.
Our short responses to these items are as follows:
Regarding 1 and 2, the Jobst Vascular Center experience with
tumescent anesthesia and RFA parallels theirs in large number,
excellent results, and patient satisfaction. Tumescent anesthesia has
been a fundamental component of the RFA procedure; however, it
is not central to the issues addressed by this study.
Regarding 3 and 4, regular post-treatment ultrasound fol-
low-up with standard venous settings often fails to detect small
arteries and veins. Increased sensitivity is needed. For example, all
patients with telangiectasias have small vessel networks. A signifi-
cant proportion of patients treated for saphenous vein insufficiency
have telangiectasias. Most of these patients continue to have small
vessel networks after RFA. However, to detect these small vessels
with low flow volume and low velocities, special ultrasound set-
tings must be used to increase color-flow sensitivity. For this study,
flow sensitivity was increased twofold by decreasing the velocity
scale as affected by pulse repetition frequency. Moreover, color
gain was maintained just below noise levels to ensure maximal
sensitivity. These techniques, combined with avoidance of probe
compression, are essential to follow-up testing.
Regarding 5, inflammation may occur or reoccur long after
the effects of tumescent anesthesia have disappeared. One possible
explanation is the process of thrombosis-recanalization—throm-
bosis that occurs in untreated vein segments adjacent to the treated
saphenous vein as well as the treated vein itself. For example, large
vein valve sinuses may not degenerate and may respond differently
than intervalve segments with smaller diameters. Vein valve sinuses
connected to small tributaries have been a preferred location for
thrombosis and small segment recanalization.
It may be that ligation at the saphenofemoral junction de-
creases the number of normal vessels. It also decreases the potential
for thrombosis-recanalization of the proximal segment of the great
saphenous vein. Without ligation, thrombus may extend beyond
the initiation of RFA, stimulating an inflammatory reaction that
then stimulates the development of small arteries and veins.
Regarding 6, we regret our oversight in not including at least
1 of the 5 references of their work. In our behalf, however, we
would like to mention that references 1 and 2 of their letter were
cited in our previous publication describing the fate of the great
saphenous vein after RFA (Vasc Endovasc Surg 2004;38:339-
344). References 3 and 4 focused specifically on tumescent anes-
thesia, which wasn’t the point of our paper, and reference 7 was too
recent to be cited. Given the limit of references properly imposed
by the editors, we believe that the references selected for this paper
are appropriate.
We also support efforts to share information across specialties
and endorse their reasons. We hope that both their comments and
our reply contribute to this objective.
Sergio X. Salles-Cunha, PhD
Jobst Vascular Center
Toledo, Ohio
doi:10.1016/j.jvs.2005.02.014
Regarding “Deep vein thrombosis after
radiofrequency ablation of greater saphenous vein: A
word of caution”
We read this excellent article (J Vasc Surg 2004;40:500-4)
with interest. We agree with the authors that several factors are
involved in luminal obliteration and that a postoperative duplex
scan is mandatory in the first week after ablation to check for deep
vein thrombosis (DVT) and flow in the deep veins and greater
saphenous vein (GSV). We also agree that the reporting of adverse
events should be unbiased and above commercial interests. The
authors report a 16% incidence of early DVT. This is in contrast to
our results.
Our experience with radiofrequency ablation (RFA) extends
over a 5-year period and consists of 90 patients (26 men, 64
women) with a mean age of 45 years (range, 15 to 80). Most were
CEAP class 2 to 4. All cases were performed under general anaes-
thesia, and patients underwent stab avulsions after ablation. Our
operating equipment was similar to that of the authors. All of our
patients had at least one duplex scan during the first week, per-
formed by experienced personnel who followed a strict protocol.
None of our patients developed early DVT. Our 67th patient had
a thrombus situated at the saphenofemoral junction, with normal
flow and no thrombus in the femoral vein, and was anticoagulated
for 3 months.
Our method differs from the authors’ in the following re-
spects:
1. No routine preoperative screening for hypercoagulability
was done unless indicated.1
2. All patients received a single, subcutaneous dose of prophy-
lactic tinzaparin sodium (3,500 U) immediately before sur-
gery.
3. A guidewire was not used routinely for placement of the
ablation catheter.
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